SCHEMBL345562

SCHEMBL345562

Oc1cccc2nc3ccccc3nc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 1.00
MAPT P10636 3/20 1.00
RAB9A P51151 2/20 1.00
GAA P10253 1/20 1.00
KMT2A Q03164 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
ACHE P22303 1/20 0.86
NQO2 P16083 5/20 0.68
CYP1A2 P05177 2/20 0.55
MYC P01106 1/20 0.53
MAX P61244 1/20 0.53
METAP2 P50579 2/20 0.45
MMP2 P08253 1/20 0.45
CHRM1 P11229 1/20 0.45
TSHR P16473 1/20 0.45
COMT P21964 1/20 0.45
ADRA1A P35348 1/20 0.45
METAP1 P53582 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20475303 0.98 ALDH1A1 (0.95) ALDH1A1MAPTRAB9AGAAKMT2A
SCHEMBL3181469 0.93 ACHE (1.00) ALDH1A1MAPTRAB9AGAAKMT2A
SCHEMBL13439504 0.90 ACHE (0.85) ALDH1A1MAPTRAB9AGAAKMT2A
SCHEMBL18387564 0.87 ALDH1A1 (0.77) ALDH1A1MAPTRAB9AGAAKMT2A
SCHEMBL3244933 0.84 ALDH1A1 (0.71) ALDH1A1MAPTRAB9AGAAKMT2A
SCHEMBL31011404 0.84 ALDH1A1 (0.71) ALDH1A1MAPTRAB9AGAAKMT2A
SCHEMBL3728001 0.84 ALDH1A1 (0.71) ALDH1A1MAPTRAB9AGAAKMT2A
SCHEMBL762952 0.83 ACHE (0.72) ALDH1A1MAPTRAB9AGAAKMT2A
SCHEMBL20272058 0.81 ACHE (0.69) ALDH1A1MAPTRAB9AGAAKMT2A
SCHEMBL18387448 0.81 NQO2 (1.00) ALDH1A1MAPTRAB9AGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122051299-A Method for recovering capacity of water system organic flow battery 中国科学院大连化学物理研究所 2026-05-15 CN claimed
US-20260091089-A1 Pyocyanine Demethylases and related Phenazine Degrading Agents Compositions, Methods and Systems for Interfering with Viability of Bacteria CALIFORNIA INST OF TECHN (US) 2026-04-02 US claimed
US-20250341489-A1 AN ELECTROCHEMICAL SENSOR AND METHOD FOR DETECTING PATHOGENIC METABOLITES DURHAM UNIVERSITY (GB) 2025-11-06 US claimed
US-12444759-B1 Ultra-high stability phenazine-based electrolyte for alkaline aqueous organic redox flow battery (AORFB), and flow battery SUZHOU LABORATORY (CN) 2025-10-14 US claimed
US-12427188-B2 Pyocyanine demethylases and related phenazine degrading agents compositions, methods and systems for interfering with viability of bacteria CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-09-30 US claimed
US-20250228880-A1 REDOX-ACTIVE COMPOUNDS AND RELATED COMPOUNDS, COMPOSITIONS, METHODS AND SYSTEMS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2025-07-17 US claimed
CN-119874764-A Phenazine vanadium compound and method for synthesizing cycloalkyl alcohol and cycloalkyl ketone by selective catalytic oxidation of cycloalkane 中国石油化工股份有限公司 2025-04-25 CN claimed
EP-4533076-A1 AN ELECTROCHEMICAL SENSOR AND METHOD FOR DETECTING PATHOGENIC METABOLITES University of Durham (GB) 2025-04-09 EP claimed
CN-115656379-B Extraction method of phthalate and polycyclic aromatic hydrocarbon in blood 遵义医科大学 2025-03-25 CN claimed
CN-118867328-B Super-stability phenazine alkaline aqueous organic flow battery electrolyte and flow battery 苏州实验室 2025-02-07 CN claimed
EP-1558585-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS Prana Biotechnology Ltd (AU) 2005-08-03 EP claimed
WO-2004031161-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2004-04-15 WO claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-0830709-B1 ELECTROLYTE MATERIALS CONTAINING HIGHLY DISSOCIATED METAL ION SALTS MOLTECH CORP (US) 2001-07-04 EP claimed
US-5837390-A Metal complex, method for producing the same and optical device SONY CORPORATION (JP) 1998-11-17 US claimed
WO-1996029753-A9 ELECTROLYTE MATERIALS CONTAINING HIGHLY DISSOCIATED METAL ION SALTS 1997-01-16 WO claimed
WO-1996029753-A1 ELECTROLYTE MATERIALS CONTAINING HIGHLY DISSOCIATED METAL ION SALTS MOLTECH CORPORATION (US) 1996-09-26 WO claimed
US-5538812-A ELECTROLYTIC CELLS WITH POLYETHERSILOXANES WITH GROUPS OF TRIFLUOROMETHANESULFONYL MOLTECH CORPORATION (US) 1996-07-23 US claimed
EP-0502964-B1 USE OF COMPLEX LIGANDS FOR IONS IN FERROELECTRIC LIQUID CRYSTAL MIXTURES HOECHST AG (DE) 1995-02-22 EP claimed
EP-0377357-B1 Process for the condensation of at least one epoxide on at least one cyclic anhyhride in the presence of a titanium-based catalyst INST FRANCAIS DU PETROLE (FR) 1994-03-23 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250228880-A1 REDOX-ACTIVE COMPOUNDS AND RELATED COMPOUNDS, COMPOSITIONS, METHODS AND SYSTEMS TXN2, SQOR, LPO ALDH1A1 720/4885MAPT 2622/4885RAB9A 2637/4885
US-12427188-B2 Pyocyanine demethylases and related phenazine degrading agents compositions, methods and systems for interfering with viability of bacteria KDM5C, KDM5A, KDM3A ALDH1A1 1384/4885MAPT 3647/4885RAB9A 1699/4885
US-20260091089-A1 Pyocyanine Demethylases and related Phenazine Degrading Agents Compositions, Methods and Systems for Interfering with Viability of Bacteria KDM5C, KDM5A, KDM1B ALDH1A1 1630/4885MAPT 4612/4885RAB9A 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.